Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter  (177Lu-PSMA) after and alpha emitter (radium-223).

Authors:

Sartor AO, la Fougere C, Essler M, et al.

Year

2020

Conference

ASCO Annual Meeting

Location

Virtual

Start Date

May 29

End Date

Jun 2